SNSE - Sensei Biotherapeutics, Inc.
Sensei Biotherapeutics, Inc. (SNSE) is a biopharmaceutical firm dedicated to discovering and advancing immunotherapies, primarily for cancer treatment. The company's innovative approaches include its proprietary ImmunoPhage platform.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $18.6M
- Beta
- -0.23
- 52-Week Range
- 6.325-36.76
- CEO
- Christopher W. Gerry
- Employees
- 14
- IPO Date
- Feb 4, 2021
- Exchange
- NASDAQ
SNSE Options Snapshot
Options pricing data for SNSE is refreshed daily after the close. When listed contracts exist, this page surfaces the latest at-the-money implied volatility, max pain strike, dealer gamma exposure (GEX), and 25-delta skew. Listed contracts and live snapshots appear once the options chain has been published by the exchange for the most recent session.
What This Page Covers
The SNSE overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.